대장직장암에서 수술 전 생검 조직의 범내피세포와 림프관 표지자 발현의 의의
Purpose: Panendothelial markers such as factor VIII, CD34, CD31, CD105 (endoglin) and D2-40 are useful to identify proliferating endothelium that is related to tumor invasion. This study was designed to identify the correlation between the expressions of panendothelial and lymphatic vessel markers i...
Saved in:
Published in | Annals of surgical treatment and research Vol. 73; no. 2; pp. 138 - 145 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | Korean |
Published |
대한외과학회
01.08.2007
|
Subjects | |
Online Access | Get full text |
ISSN | 2288-6575 2288-6796 |
Cover
Summary: | Purpose: Panendothelial markers such as factor VIII, CD34, CD31, CD105 (endoglin) and D2-40 are useful to identify proliferating endothelium that is related to tumor invasion. This study was designed to identify the correlation between the expressions of panendothelial and lymphatic vessel markers in preoperative biopsy specimens and the clinicopathologic factors.
Methods: Preoperative biopsy specimens from 72 patients were immunostained for CD105, CD34, CD31, Factor VIII and D2-40. The microvessel and lympathic vessel densities (MVD and LVD) were counted in dense vascular foci (hot spots) on a ×200 field in each specimen. The correlation between these factors and the clinicopathologic parameters were analyzed.
Results: The MVD by CD105 showed statistically significant correlation with tumor emboli, the T-stage, nodal metastasis and the stage, and the MVD by CD34 had statistically significant correlation with tumor emboli, nodal metastasis and the stage. The lympathic vessel density (LVD) by D2-40 showed a statistically significant correlation with tumor emboli, the T-stage and nodal metastasis.
Conclusion: The MVD by CD105 and the LVD by D2-40 in preoperative biopsy specimens of colorectal cancers may be useful markers for the prediction of invasiveness. (J Korean Surg Soc 2007;73:138-145) KCI Citation Count: 0 |
---|---|
Bibliography: | G704-000991.2007.73.2.006 |
ISSN: | 2288-6575 2288-6796 |